Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

Phase 2

Completed

• Conditions: Arterial Occlusive Diseases; Peripheral Vascular Diseases; Thrombosis

• Registration Number: NCT00073554
• Lead Sponsor: ARCA Biopharma, Inc.

Brief Summary

This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

Detailed Description

Not available

Study Timeline

• Study Start: 2003-06
• Study First Submitted: 2003-11-24
• Study First Submitted QC: 2003-11-25
• Study First Posted: 2003-11-26
• Status Verified: 2006-11
• Last Update Submitted: 2009-12-16
• Last Update Posted: 2009-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States